Safety and Efficacy of Adalimumab for Patients With Moderate to Severe Crohn's Disease: The Taiwan Society of Inflammatory Bowel Disease (TSIBD) Study

Abstract

Background/AimsOnly moderate to severe Crohn's Disease (CD) patients without a satisfactory conventional therapy effect are eligible to get reimbursement from the National Health Insurance of Taiwan for using adalimumab. These are more stringent criteria than in many Western countries and Japan and Korea. We aim to explore the efficacy of using adalimumab in CD patients under such stringent criteria.MethodsA retrospective analysis was conducted in nine medical centers in Taiwan and we collected the results of CD patients receiving adalimumab from Sep 2009 to Mar 2014. The clinical characteristics, response measured by CDAI (Crohn's Disease Activity Index), adverse events and survival status were recorded and analyzed. CR-70, CR-100, and CR-150 were defined as attaining a CDAI decrease of 70, 100 or 150 points compared with baseline.ResultsA total of 103 CD patient records were used in this study. Sixty percent of these patients received combination therapy of adalimumab together with immunomodulators. CR-70 was 68.7%, 74.5% and 88.4% after week 4, 8 and 12 of treatment, respectively. The steroid-free rate, complications and survival were 47.6%, 9.7% and 99% of patients, respectively. In considering the mucosal healing, only 25% patients achieve mucosal healing after treatment for 6 to 12 months. Surgery was still needed in 16.5% of patients. Combination treatment of adalimumab with immunomodulators further decreased the level of CDAI at week 8 when compared with the monotherapy.ConclusionsEven under the stringent criteria for using adalimumab, the response rate was comparable to those without stringent criteria.

Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled Trials

“…Biological agents, especially anti-TNF antibodies, have been approved by the FDA for treating some kinds of autoimmune diseases and achieved the desired effect. 24 – 27 Now the most widely used anti-TNF-α antibodies in clinic is IFX. However, its high immunogenicity and high rate of AE, as well as inconvenient mode of administration, limit its applications to some extent.…”

Efficacy of Adalimumab in Korean Patients with Crohn's Disease

“… 4 Adalimumab has become a new treatment option for patients with CD who are either naive to, failed to respond to, or experienced loss of response to infliximab therapy. 5 – 9 Adalimumab, a recombinant, fully humanized immunoglobulin G1 monoclonal antibody, is theoretically less vulnerable to immunogenicity development. This drug has proved effective for remission induction and maintenance in Western CD patients.…”

Metabolism of Anandamide by Human Cytochrome P450 2J2 in the Reconstituted System and Human Intestinal Microsomes

“…IBD is characterized by severe diarrhea, abdominal pain, fatigue, nausea, and weight loss due to malnutrition. Moreover, a person diagnosed with IBD has an increased risk of developing colon cancer (Moran et al, 2013;Chang et al, 2014;Seo and Chae, 2014). Although the cause(s) of IBD is unknown, studies suggest that autoimmune reactions, genes, and the environment all may contribute to its development (Kozak et al, 2002b;Stanley and O'Sullivan, 2014;Curkovic et al, 2013;Yarlas et al, 2015).…”

“…Medicinal interventions include aminosalicylates (Yarlas et al, 2015), corticosteroids (Kuenzig et al, 2014), immunomodulators (Amin et al, 2015), anti-tumor necrosis factor therapies (Chang et al, 2014;Seo and Chae, 2014), as well as medications used primarily to treat accompanying symptoms, such as pain, infections, and diarrhea. Complications and failure of pharmaceuticals often make surgery a necessity for many patients with IBD (Moody et al, 2001).…”